We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
Read MoreHide Full Article
Boston Scientific Corporation (BSX - Free Report) recently announced favorable data supporting the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data included one-year results from the EMINENT trial, which showed that the Eluvia stent was superior in comparison to the self-expanding bare metal stents (BMS) for the treatment of patients with peripheral artery disease (PAD) and lesions up to 210 mm in length in the superficial femoral artery (SFA) or popliteal artery (PPA).
Per management, the EMINENT trial establishes the Eluvia stent as the first drug-eluting stent to achieve superior primary patency rates compared to bare metal stents in a head-to-head randomized study. As the only company that offers both a drug-coated balloon and a drug-eluting stent to treat patients with PAD, Boston Scientific’s broad range of offerings provides physicians with evidence-based and highly differentiated treatment alternatives.
The results of the study are likely to bolster Boston Scientific’s Peripheral Interventions portfolio.
EMINENT Study in Detail
The EMINENT study enrolled 775 patients, thus becoming the largest randomized trial of a drug-eluting stent for the treatment of PAD to date. The study demonstrated a primary patency rate of 85.4% compared to 76.3% with BMS. The study also found that patients treated with the Eluvia stent exhibited a considerably higher rate of sustained clinical improvement without reintervention (with 83% for Eluvia stent and 76.6% for those treated with BMS). In addition, after one year, there was no significant difference found in major adverse events or all-cause mortality rates between patients who received treatment with Eluvia stent and those treated with BMS.
Image Source: Zacks Investment Research
This EMINENT study adds to the robust body of evidence from the IMPERIAL trial and confirms that the Eluvia stent should be regarded as the stent of choice for treating SFA and PPA lesions of intermediate length.
Few Words on Eluvia Stent
The Eluvia stent was created for the treatment of PAD, which, per the company-provided data, affects around 8.5 million people in the U.S. and more than 200 million people worldwide. The Eluvia stent utilizes a drug-polymer combination to prevent tissue re-growth. It facilitates sustained release of the lowest dose of paclitaxel of any peripheral drug-eluting device, re-opens blocked arteries and restores blood flow.
Industry Prospects
Per a report published in Allied Market Research, the peripheral artery disease market is expected to see a CAGR of 8.5% from 2020 to 2027. Rapid surge in the geriatric population and subsequent growth in prevalence of PAD, increasing product approvals and rising cases of diabetes are driving the market during the forecast period.
Given the market prospects, the positive findings of the EMINENT study backing the Eluvia stent for PAD treatment seem strategic for Boston Scientific.
Other Data Presentations at VIVA Meeting
During a late-breaking clinical trial presentation at the VIVA meeting, Boston Scientific reported positive results for the EkoSonic Endovascular System (EKOS system). The safety and efficacy of the EKOS system in treating patients with intermediate-high and high-risk pulmonary embolism were confirmed by data from the KNOCOUT PE registry. Physicians making vital evidence-based decisions for their patients, in often emergency treatment situations, are encouraged by the findings in this registry analysis.
The company also reported positive results for the Ranger Drug-Coated Balloon (DCB). The data included two-year results from the RANGER II SFA randomized controlled trial, which confirmed the Ranger DCB's safety and efficacy in treating patients with PAD in the superficial femoral artery and proximal popliteal artery when compared to standard percutaneous transluminal angioplasty. These two-year results show a sustained, high efficacy rate, even in individuals with more complex lesion subtypes.
Share Price Performance
The stock has outperformed its industry over the past year. It has grown 2.9% compared with the industry’s 0.3% growth.
Zacks Rank and Key Picks
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space include Horizon Therapeutics Public Limited Company , Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and AMN Healthcare Services Inc (AMN - Free Report) .
Image: Bigstock
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
Boston Scientific Corporation (BSX - Free Report) recently announced favorable data supporting the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data included one-year results from the EMINENT trial, which showed that the Eluvia stent was superior in comparison to the self-expanding bare metal stents (BMS) for the treatment of patients with peripheral artery disease (PAD) and lesions up to 210 mm in length in the superficial femoral artery (SFA) or popliteal artery (PPA).
Per management, the EMINENT trial establishes the Eluvia stent as the first drug-eluting stent to achieve superior primary patency rates compared to bare metal stents in a head-to-head randomized study. As the only company that offers both a drug-coated balloon and a drug-eluting stent to treat patients with PAD, Boston Scientific’s broad range of offerings provides physicians with evidence-based and highly differentiated treatment alternatives.
The results of the study are likely to bolster Boston Scientific’s Peripheral Interventions portfolio.
EMINENT Study in Detail
The EMINENT study enrolled 775 patients, thus becoming the largest randomized trial of a drug-eluting stent for the treatment of PAD to date. The study demonstrated a primary patency rate of 85.4% compared to 76.3% with BMS. The study also found that patients treated with the Eluvia stent exhibited a considerably higher rate of sustained clinical improvement without reintervention (with 83% for Eluvia stent and 76.6% for those treated with BMS). In addition, after one year, there was no significant difference found in major adverse events or all-cause mortality rates between patients who received treatment with Eluvia stent and those treated with BMS.
Image Source: Zacks Investment Research
This EMINENT study adds to the robust body of evidence from the IMPERIAL trial and confirms that the Eluvia stent should be regarded as the stent of choice for treating SFA and PPA lesions of intermediate length.
Few Words on Eluvia Stent
The Eluvia stent was created for the treatment of PAD, which, per the company-provided data, affects around 8.5 million people in the U.S. and more than 200 million people worldwide. The Eluvia stent utilizes a drug-polymer combination to prevent tissue re-growth. It facilitates sustained release of the lowest dose of paclitaxel of any peripheral drug-eluting device, re-opens blocked arteries and restores blood flow.
Industry Prospects
Per a report published in Allied Market Research, the peripheral artery disease market is expected to see a CAGR of 8.5% from 2020 to 2027. Rapid surge in the geriatric population and subsequent growth in prevalence of PAD, increasing product approvals and rising cases of diabetes are driving the market during the forecast period.
Given the market prospects, the positive findings of the EMINENT study backing the Eluvia stent for PAD treatment seem strategic for Boston Scientific.
Other Data Presentations at VIVA Meeting
During a late-breaking clinical trial presentation at the VIVA meeting, Boston Scientific reported positive results for the EkoSonic Endovascular System (EKOS system). The safety and efficacy of the EKOS system in treating patients with intermediate-high and high-risk pulmonary embolism were confirmed by data from the KNOCOUT PE registry. Physicians making vital evidence-based decisions for their patients, in often emergency treatment situations, are encouraged by the findings in this registry analysis.
The company also reported positive results for the Ranger Drug-Coated Balloon (DCB). The data included two-year results from the RANGER II SFA randomized controlled trial, which confirmed the Ranger DCB's safety and efficacy in treating patients with PAD in the superficial femoral artery and proximal popliteal artery when compared to standard percutaneous transluminal angioplasty. These two-year results show a sustained, high efficacy rate, even in individuals with more complex lesion subtypes.
Share Price Performance
The stock has outperformed its industry over the past year. It has grown 2.9% compared with the industry’s 0.3% growth.
Zacks Rank and Key Picks
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space include Horizon Therapeutics Public Limited Company , Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and AMN Healthcare Services Inc (AMN - Free Report) .
Horizon Therapeutics, carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 16.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals, which carries a Zacks Rank #1, has a long-term earnings growth rate of 9.8%.
AMN Healthcare, sporting a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 10.5%.